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Abstract
Background: Although store-and-forward teledermatology is increasingly becoming popular, evidence on its
effects on efficiency and costs is lacking. The aim of this study, performed in addition to a clustered randomised
trial, was to investigate to what extent and under which conditions store-and-forward teledermatology can reduce
costs from a societal perspective.
Methods: A cost minimisation study design (a model based approach) was applied to compare teledermatology
and conventional process costs per dermatology patient care episode. Regarding the societal perspective, total
mean costs of investment, general practitioner, dermatologists, out-of-pocket expenses and employer costs were
calculated. Uncertainty analysis was performed using Monte Carlo simulation with 31 distributions in the used cost
model. Scenario analysis was performed using one-way and two-way sensitivity analyses with the following
variables: the patient travel distance to physician and dermatologist, the duration of teleconsultation activities, and
the proportion of preventable consultations.
Results: Total mean costs of teledermatology process were €387 (95%CI, 281 to 502.5), while the total mean costs
of conventional process costs were €354.0 (95%CI, 228.0 to 484.0). The total mean difference between the
processes was €32.5 (95%CI, -29.0 to 74.7). Savings by teledermatology can be achieved if the distance to a
dermatologist is larger (> = 75 km) or when more consultations (> = 37%) can be prevented due to
teledermatology.
Conclusions: Teledermatology, when applied to all dermatology referrals, has a probability of 0.11 of being cost
saving to society.
In order to achieve cost savings by teledermatology, teledermatology should be applied in only those cases with a
reasonable probability that a live consultation can be prevented.
Trail Registration: This study is performed partially based on PERFECT D Trial (Current Controlled Trials No.
ISRCTN57478950).
Background
Teledermatology can be defined as the use of imaging
and telecommunication technologies to provide skin ser-
vices by a dermatologist to another health professional
or a patient [1]. Teledermatology can be useful to
increase access to care in rural and remote areas [2],
but can also potentially decrease the need for outpatient
hospital consultations and, as a consequence, reduce
societal costs of skin treatment.
Based on logistics and technical equipment, two types
of teledermatology can be distinguished: real-time and
store-and-forward (SAF). In real-time teledermatology
synchronous communication is established using video-
conferencing equipment. The SAF variant is less
demanding due to its asynchronous communication by
e-mail or a web-based application and therefore perhaps
less costly. Hence, the popularity of SAF teledermatol-
ogy is increasing, even in densely populated countries
with small distances. Still, evidence of decreasing
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due to teledermatology is currently lacking [1,3]. In par-
ticular, economic evaluations of SAF teledermatology
services in comparison to conventional dermatological
care are lacking [1,4].
We conducted a clustered randomised trial (PERFECT
D: Primary care Electronic Referrals: Focus on Efficient
Consultation using Telemedicine in Dermatology,t r i a l
registration: Current Controlled Trials No:
ISRCTN57478950) to assess whether teledermatology,
used as an electronic SAF referral system, could
decrease the number of outpatient hospital referrals by
the general practitioner (GP) [5]. In our teledermatology
setting, the GP could ask the dermatologist advice on
how to treat their dermatological patients. The main
objective of the economic evaluation study described in
this paper was to investigate to what extent and under
which conditions SAF teledermatology can reduce the
costs from a societal perspective.
Methods
Clustered RCT on teledermatology
The PERFECT D study was performed in the catch-
ments areas of two Dutch general district hospitals in
Almere and Zeist. Patients were eligible if they were
referred by their GP to one of the recruited dermatolo-
gists, did not require an urgent consultation (within one
or two days) and gave written informed consent. We
randomised GPs in two groups: an intervention and a
control group. Intervention group GPs took at least two,
maximally four digital images of the skin problem and
attached these to a semi-structured form which they
completed on a secured website. We used KSYOS
TDCS® teledermatology website which was adjusted for
the study (anonymous patient data) and a KODAK
CX6230 digital camera. The dermatologist to whom the
patient was assigned received a notification email and
responded within two days using the same secured web-
site. Based on digital images and semi-structured form,
the dermatologist advised the GP about further proce-
dures such as treatment, additional investigations, need
for standard or urgent referral that GP could perform.
In control practices, patients were referred to a der-
matologist following the usual care process. For the pur-
pose of this study, all patients from the intervention and
control group were required to visit a dermatologist in
the outpatient hospital clinic and were placed on the
regular waiting list (can take up to twelve weeks in
some hospitals), irrespective of their degree of recovery.
During this visit the dermatologist determined whether
the live consultation was appropriate (e.g. the required
intervention can only be performed by a dermatologist)
or not (e.g. the patient was already recovered because of
teledermatology or spontaneously). A consultation was
also considered preventable if a dermatologist concluded
a GP could also have treated a patient instead of refer-
ring the patient.
Eighty-five GPs and five dermatologists participated in
the trial including 631 patients (intervention: 327, con-
t r o l :3 0 4 ) .O u rt r i a ls h o w e dt hat using teledermatology
in general practice made 39% of consultations preventa-
ble, while this percentage was 18.3% in the control
group. It was concluded that 20.7% of dermatological
consultations were preventable due to teledermatology.
The ethics committee considered this study to be
exempt from review because the research did not inter-
fere with usual care. Details and the results from the
clustered randomised trial (PERFECT D) have been
described separately [5].
Design of the economic evaluation
Teledermatology reorganizes the care process of skin
patients by shifting responsibilities between primary and
secondary care, but it does not imply a different, new
treatment for these patients. Although teledermatology
can lead to an earlier diagnosis and thereby earlier treat-
ment, after a certain period patients are equally recov-
ered with or without teledermatology. A recent study
demonstrated that differences regarding clinical out-
comes between conventional care and teledermatology
care did not exist, which justified a cost minimisation
study design [6,7].
The economic evaluation was performed following a
decision analytical approach [8]. A model was built con-
taining the volume and unit cost parameters of the tele-
dermatology and conventional process. The time
horizon was defined as the length of the dermatological
episode of care, starting with the referral of the patient
by a GP to a dermatologist and ending within six
months after the referral. This time horizon was chosen
as it was expected that within this period all dermatolo-
gical patients would be equally recovered. This period
was equal for the conventional and teledermatology pro-
cess. In the trial, control and intervention patients (even
when they were recovered) had similar waiting times up
to six months to visit a dermatologist [5]. The study by
Pak et al. [6] showed equal recovery after four months.
As our time horizon was less than a year, no discount-
ing was applied.
Five major costs components were distinguished:
investments, GP care, dermatology care, out-of-pocket
expenses by patients, and employer costs (see Figure 1
and Table 1). In total 282 variables were used in the
model.
The investments covered the costs of the digital cam-
era, website application (development, hosting and
maintenance) and training of the GPs and dermatolo-
gists. The website is a stand-alone web-based application
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tologists’ office.
The costs of the internet connection and computer
expenses were not taken into account as almost all GP
practices and all dermatologists were already well pro-
vided. The yearly costs of investments were calculated
from depreciation over three years of the original price.
The investment costs were calculated regarding a wide
implementation in the Netherlands, for all GPs and der-
matologists. We assumed that a GP uses the equipment
for 60 patients per year (1,5 per week) [9].
The costs of conventional GP care only consisted of
the first consultation costs (duration of consultation
with referral to a dermatologist), while teledermatology
GP care costs also contained the costs of the diagnostics
and treatment following the teledermatology advice, as
well as subsequent follow-up visits. The duration of the
teledermatology activities in a GP practice was estimated
in a separate laboratory study among eight GPs with
eight patients each [10].
Costs of diagnostics and treatment were estimated by
calculating the average costs of diagnostics and treat-
ment associated with six out of ten diagnoses for which
Dutch patients are most often referred to a dermatolo-
gist [9]. The other four top ten diagnoses (local redness,
local swelling, other skin diseases and other benign skin
diseases) were not specified well enough to find out the
kind of diagnostic and therapeutic measures they imply.
Therefore, the final list of diagnoses included 6 instead
of 10 diagnoses. Diagnostics and treatment costs in gen-
eral practice were estimated for those 6 most frequently
observed dermatological diagnoses referred by GPs. In
case of teledermatology, costs of diagnostics and treat-
ment were put partially (percentage of preventable con-
sultations) on the GPs side and partially on the
dermatologists’ side. In case of conventional care, all
diagnostic and treatment costs were put on the derma-
tologists’ side. The costs of diagnostics and treatment
included only the costs of medication and intervention,
while the costs of consultation were separately included
in the model.
Two dermatologists provided the following informa-
tion about each diagnosis: most frequently used diagnos-
tic tests and treatment, in which proportion of the cases
they were used and how often a treatment was repeated
within a care episode. The dermatological dictionary
(http://www.huidziekten.nl, last accessed: October 2007)
was used to retrieve further information, verify and
complete the list of diagnostic tests and treatments. For
each diagnostic test a tariff was used from the Tariff
Book of Medical Specialists (http://www.nza.nl, last
accessed: October 2007). In order to retrieve the costs
of medications, the Pharmaceutical Compass (PhC,
Dutch registry of medications) was used. If a drug was
Figure 1 Graphical representation of the model where the choice is made between the conventional and teledermatological process.
The key components of these processes are illustrated.
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Page 3 of 10Table 1 Parameter estimates and related uncertainty for a selection of most important volume components and unit
costs
Value Uncertainty
analysis (UA)
**
Scenario
analysis (SA)
Range Distribution parameters
(T: Triangular/
b: beta(integral form))
Source
Investment costs
Digital camera price per 3 years € 175 UA 50 -
300
T (mode = 175) Market prices
Website application
development for 3 years
€ 40 k UA 20 k -
70 k
T (mode = 40 k) Expert opinion
Number of accounts using the
service
5000 UA 2000 -
8000
T (mode = 5000) Expert opinion
Duration training GP (minutes) 35 UA 10 -
50
T (mode = 35) Trial observation
Duration training dermatologist
(minutes)
20 UA 5 - 35 T (mode = 20) Trial observation
Trainer hourly rate € 16.6 UA 10 -
25
T (mode = 16.6) Expert opinion
GP
Duration consultation (minutes) 8.1 Nivel [9]
Costs GP per minute € 2.5 Dutch Manual for Costing [11]
Duration teleconsultation
activities (minutes)
11.6 UA, SA 4.6 -
28.8
This parameter consists of
nine different parameters
9
Trial data [10]
Dermatologist
Duration consultation (minutes) 10 NA Dutch Manual for Costing [11]
Costs dermatologist per minute € 5.6
(academic),
€ 6.7
(general)
NA Dutch Manual for Costing [11]
Teleconsultation duration
(minutes)
8.3 UA, SA 4.5 -
13.1
This parameter consists of
three different parameters
Trial observation
Diagnostics and treatment € 87.6 UA 60
-115
Diagnosis T (mode = 50)
Treatment (mode = 40)
Calculated based on prevalence information,
guidelines, expert opinions and tariff books
Number of visits per episode 3 UA 1-5 T (mode = 3) Expert opinion
Out-of-pocket
Distance to GP (km) 1.8 SA 1 - 60 NA Dutch Manual for Costing [11]
Distance to dermatologist (km) 7 SA 3 -
200
NA Dutch Manual for Costing [11]
Travel costs per km, public
transportation or car
€ 0.25 NA NA Dutch Manual for Costing [11]
Parking costs per visit € 2.5 NA NA Dutch Manual for Costing [11]
Proportion patients visiting a GP
or dermatologist in company
0.2 UA 0-0.5 b (r = 2, n = 10) Educated guess based on proportion of
elderly and children
Employer costs
Duration one visit GP (minutes)
*
33.2 UA 25 -
40
Consists of several
parameters*
Dutch Manual for Costing [11] + estimation
Duration one visit dermatologist
(minutes)*
71 UA 40 -
100
Consists of several
parameters*
Dutch Manual for Costing [11] + estimation
Costs per hour € 35 UA 10 -
50
T (mode = 35) Based on average income in the Netherlands
General
Proportion of preventable
referrals
0.20 UA, SA 0.1 -
0.50
b (r = 4, n = 19) Trial data [5]
*travel time, waiting time, consultation time, time picking up medication
** Other parameters included in the uncertainty analysis included: number of account teleconsultation system (T (min 2000, mode 5000, max 8000)) and
parameters concerning the waiting time in the GP and dermatologist office.
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brand name, was searched for on the pharmacy websites
to obtain data about their costs. Multiple expert opi-
nions were similar and therefore easily to aggregate by
taking the average. Finally, general prevalence data of
the six diagnoses were used to derive a weighted average
of the use of health care resources.
Costs of dermatology care included consultation costs
(first consultation and follow-up), costs of diagnostics
and treatment, and the teleconsultation costs during the
teledermatology process. The consultation costs were
calculated based on the consultation costs per minute
including medical staff, hospital housing and overhead
[11]. The duration of teleconsultation activities was
retrieved from observations of dermatologists during the
trial. This information was verified by analysing the log-
ging information from the website application. In 14%
of necessary consultations, the dermatologists in our
trial indicated that teledermatology shortened the first
dermatological consultations remarkably (10%). This
finding was incorporated in the model as a variable (dis-
tribution, beta integral form: n = 3, r = 30) for the tele-
dermatology consultations that are not prevented.
Diagnostic and treatment costs in dermatological prac-
tices were estimated following a similar procedure as
used in GP practices. For the unit costing of consulta-
tions by a dermatologist we distinguished teaching and
non-teaching hospitals and calculated a weighted aver-
a g eu n i tc o s tg i v e nt h ef a c tt h a t1 0 %o fD u t c hh o s p i t a l s
are teaching hospitals [10].
Out-of-pocket expenses consisted of travel costs of the
patient and, if opportune, of an accompanying person.
We estimated (based on trial population) that about
20% of patients (children and elderly) visit a health pro-
fessional in company. Out-of-pocket expenses related to
extra, informal help at home were not included because
we assumed that they are negligently small in the case
of dermatological conditions.
Employer costs originating from production losses at
work were derived from the time spent by the patient (GP,
dermatologist and pharmacy visit time including travelling,
waiting and actual consultation duration) and assuming
that the proportions of patients in our sample with a paid
job or working part-time resemble national averages.
Unit costs of GP and outpatient dermatological con-
sultations, average travel distances, and national esti-
mates of work participation were derived from the
Dutch Manual on Costing in Health Care Research [10].
In case no sources for the unit costs were available
(e.g. patient waiting time in the waiting room), expert
opinions and educated guesses were used. For website
development costs, hosting and maintenance a profes-
sional ICT organisation providing such services was
consulted.
Incremental cost analysis and uncertainty analysis
An incremental cost analysis was performed to demon-
strate which strategy was associated with the lowest
costs per episode of care. Additionally, a probabilistic
sensitivity analysis based on a second order Monte
Carlo simulation with 10000 simulations was performed
to study the impact of parameter uncertainty regarding
the estimated unit costs and the volume data on the
results of the incremental cost analysis.
A multivariate probabilistic sensitivity analysis was
performed with all parameters that, according to one-
way sensitivity analysis, influenced model outcome [12].
This analysis resulted in 31 parameters. A linear regres-
sion of the cost difference between teledermatology and
the conventional process with the sampled distributions
as covariates identified the following top five ranking of
parameters with the highest impact on the difference
(based on the absolute value of the standardized regres-
sion coefficients in decreasing order): proportion pre-
ventable consultations, number outpatient visits per
episode, duration evaluation website teledermatologist,
proportion reduce in consultation duration first outpati-
ent consultation, and duration GP follow up
consultation.
For all 31 parameters included in this uncertainty ana-
lysis, we defined a distribution (range and type) based
on observations [10], expert opinion or available
resources [11]. The four proportions in the model fol-
lowed a beta distribution, while a triangular distribution
w i t ht h em o s tl i k e l yv a l u ea tt h et o pw a sa s s u m e df o r
other variables (e.g. travel distance). Mean costs of the
teledermatology and conventional processes were based
on the simulation results.
Scenario analysis
After checking the face-validity of our findings by pre-
senting it at scientific meetings, we performed a scenario
analysis. The proportion of preventable consultations
was considered one of the most important variables to
decrease the costs due to teledermatology. From our
trial, it appeared that the proportion of preventable con-
sultations may vary by disease group. Therefore a range
of different proportions of preventable consultations
(10% - 50%) was used in one way sensitivity analysis to
assess the impact of their variation on changes in costs.
Our study was based on Dutch circumstances where
patient distances to GP and dermatologist are relatively
small. In order to enable comparisons with other coun-
tries, we extended these parameters in a scenario analysis.
Furthermore, as there is no standard teledermatology soft-
ware, time needed to complete teleconsultation activities
might vary in different settings. For teledermatology activ-
ities on the dermatologist side which were grouped in one
variable in the cost model, a one-way sensitivity analysis
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teledermatology activities on the GP side, one-way sensi-
tivity analysis was performed using the most consuming
GP teleconsultation activity: completing the website forms
[10]. In the trial, completing the website forms took on
average 3.2 minutes (range: 1.8 to 6.3) [10].
The middle column of Table 1 shows an overview of
the main variables considered in the uncertainty and sce-
nario analyses. Data Tree Age Pro Suite 2006 software
was used for the calculation of the costs, uncertainty and
scenario analyses (DATA Professional/DATA 4.0 Health-
care user’s manual. TreeAge Software Inc, 1998-2001).
Results
Total costs of teledermatological and conventional
processes
Mean costs of the teledermatological process per care
episode were €387 (95%CI, 281 to 502.5) and mean con-
ventional process costs were €354.0 (95%CI, 228.0 to
484.0), a total mean difference of €32.5 (95%CI, -29 to
74.7) (Table 2). Monte Carlo simulation showed that the
conventional process was less expensive than the tele-
dermatology process in 89% of all simulations (Figure 2).
Distinct cost components
Mean investment costs were €1.6 per episode and the
major part of these costs were the costs of the digital
camera. Largest differences in costs were found for the
costs of the GP and out-of-pocket costs (Table 2). The
GP costs amounted to on average €21.3 euros in the con-
ventional process and €85.5 in the teledermatological
process. This difference can be explained by the
increased first consultation costs of teledermatology GPs
which amounted to €45.6 compared to €21.3 for conven-
tional GPs as the consultations were longer. Furthermore,
during this GP consultations in teledermatology process,
also costs of diagnostics and treatment are present and
there is a follow-up consultation. Mean out-of-pocket
costs amounted to €16.3 in the conventional process and
€12.4 in the teledermatological process. Prevented outpa-
tient hospital consultations resulted in lower travel costs
which were on average €11.5 compared to €15.2 in the
conventional process. Dermatologists’ costs remained
almost the same. The reduction in live consultation low-
ered the visit costs in the teledermatology process but
that was compensated for by the costs of teleconsultation
by the dermatologist. There was almost no difference in
employer costs, with teledermatology employer costs of
€46.2 and €47.3 in the conventional process.
Scenario analysis
The scenario-analysis showed that the teledermatology
and conventional costs would have been similar (€353.3;
see Figure 3), if 37% of referrals by the GPs would have
been prevented. Increasing the proportion of preventa-
ble consultations decreased the costs of teledermatology
care. Observing a proportion of prevented referrals of
37% or higher however, is not that likely (less than 5.5
per 100 simulations).
Extending average patient travel distance to GP (up to
60 km) had a limited impact on the difference in costs,
but for the distance to the hospital (up to 200 km) a
break even point at 75.1 km was noted. If a dermatolo-
gist is this far, which is not very likely in the Nether-
lands, total costs of both teledermatological and
conventional process reach €465.7 (Figure 4 and 5).
Variation in duration of GP teleconsultation regarding
completion of the website forms revealed that teleder-
matology is more expensive if the duration of complet-
ing the website forms increases. Change in
teleconsultation activities by a dermatologist resulted in
the same costs for the two processes at 2.1 minutes.
Values up to 2.1 minutes for website completion were
observed in less 1.4 per 100 simulations.
Discussion
Based on our cost model, the economic evaluation
showed that the teledermatological process was 33 euro
more expensive than the conventional process.
In the Netherlands, as in many other countries, a der-
matological consultation is more expensive than a GP
consultation. Therefore, shifting the care from a derma-
tologist to a GP practice would be preferred from an
economical point of view. However, when using teleder-
matology a GP is required to perform extra activities
such as obtaining the images and completing the web-
site forms which increases the time of a GP consulta-
tion. If a teledermatologist can advise a GP on how to
diagnose and/or treat the patient, the costs of diagnos-
tics and treatment are made in the GP practice instead
of the dermatologist office. For these reasons, the GP
costs of the teledermatology process were higher com-
pared to GP costs in the conventional process. Further-
more, although teledermatology can prevent a fifth of all
dermatology referrals [5], this did not result in cheaper
total care of dermatology patients as a dermatologist
had to review all the patients through teledermatology
to finally also see 80% of the patients live.
An important condition for applying cost minimisa-
tion analysis (CMA) design is that there is no difference
in health outcomes between the two types of care pro-
vided [7]. Pak et al. [6] assessed the clinical course of
randomly assigned patients to teledermatology or con-
ventional care. As this first large randomized trial con-
firmed our assumption for equal outcomes between the
groups after a certain period, we believe that CMA was
an appropriate study approach for the present economic
evaluation.
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Page 6 of 10Table 2 Mean costs of teledermatology and conventional process by type of costs, per episode
Teledermatology
process, €
Conventional
process, €
Incremental costs due to
teledermatology €
Total costs* Mean total (95% CI) 387.0
(281.0 to 502.5)
354.0
(228.0 to 484.0)
32.5
(-29.0 to 74.7)
Investment costs Mean total (95% CI) 1.6 (1.6 to 2.1) 0 1.6 (1.6 to 2.1)
Digital camera costs 0.8 0
Website costs 0.16 0
Training costs 0.6 0
GP costs Mean total (95% CI) 85.5
(64.8 to 111)
21.3
(13.0 to 30.1)
64.2
(46 to 88.3)
Costs of diagnosis and
treatment
18.4 0
Costs first visit 45.6 21.3
Costs follow up visit 17.6 0
Dermatologist
costs
Mean total (95% CI) 241.0
(155.4 to 338.9)
269.1
(173.8 to 363.3)
-28.1
(-90.0 to 15.6)
Costs of diagnosis and
treatment
68.9 87.3
Costs first visit 42.9 54.4
Costs follow-up visit 48.3 60.4
Teleconsultation costs 47.5 0
Out-of-pocket
costs
Mean total (95% CI) 12.4
(5.4 to 19.6)
16.3
(8.1 to 24.5)
-4.1
(-8.1 to - 1.85)
Travel costs patient 11.5 15.2
Travel costs accompanying
person
0.8 1.1
Employer costs Mean total (95% CI) 46.2
(18.4 to 86.1)
47.3
(18.0 to 83.1)
-1.1
(-14.3 to 7.6)
The 95% confidence interval (95% CI) reported in this table represents the 2.5% and 97.5% percentiles of the simulation results. For interpretation, a Bayesian
perspective on uncertainty is adopted in the text of this paper in which the probability of simulations results (e.g. teledermatology being cheaper than
conventional practice) is reported.
Figure 2 Distribution of the incremental costs of the
teledermatological against conventional process as the
reference case, following 10000 Monte Carlo simulations of 31
input distributions.
Figure 3 Total costs of teledermatology care and conventional
care (Y-as) for different proportions of consultations prevented
(X-as).
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a majority of the unit costs were derived from a stan-
dard value or were estimated from various resources. In
order to verify the robustness of our findings for reason-
able alternative parameter estimates, we performed a
Monte Carlo simulation. This uncertainty analysis
showed that the teledermatological process was more
expensive with 89% certainty. One should be aware
however, that this percentage is partly based on assumed
triangular and beta distributions in the model. Although
making such assumptions is common practice, it may
lead to over- and underestimations, depending on how
well the assumptions meet reality. The model-based
approach to assess the costs of teledermatology contains
several non-empirical parameter estimates based on
expert opinion. Also, data on for example the GP time
needed to complete the website were gathered in a con-
venience subsample of GPs.
Although these estimates may demonstrate face-validity,
we accepted broad parameter ranges to account for related
uncertainty. Given the limited use of observational data in
the present model, the conclusions should be considered
as tentative. The results on the relative impact of different
parameter estimates may be helpful in designing future
studies on the subject.
The proportion of preventable consultations (20%)
that resulted from our trial is too low to show a positive
cost effect of teledermatology compared to conventional
care. When increasing the proportion of preventable
consultations up to 40%, teledermatology was more
likely to be cheaper than conventional care. In this
study we used the dermatologists opinion about pre-
ventability of a consultation but in reality it is the GP
who decides to refer a patient for consultation.
Although we do not have data about the GPs opinion
on preventable consultations some studies showed that
using teledermatologic consultation in a GP practice
with a special interest in dermatology, such as in the
United Kingdom [13] might result in a higher propor-
tion of preventable office visits. In our trial, all patients
referred to a dermatologist were included. However, the
results implicated that the proportion of preventable
consultations varied by disease group. Teledermatology
appeared to be less suitable for nevi, but very suitable
for eczema patients. Regarding this finding, we believe
that costs saving due to teledermatology can be reached
when teledermatology would be applied in selected
groups of patients. However, in order to assess the exact
savings for the special groups, a disease-specific trial is
necessary and the cost model needs to be adjusted (e.g.,
costs of diagnosis and treatment).
Extending patient travel distances to a hospital had an
impact on the cost difference between the teledermatology
and conventional care process. If the distance to a derma-
tologist is reaching 75 km, teledermatology becomes a
cheaper option. For this reason, our study results might be
interesting for countries with larger travel distances as in
their cases teledermatology might be a cheaper option.
However, an adjustment in the cost model would be
necessary to assess this assumption (e.g., different care
models in different countries, different costs of dermatolo-
gists and GPs, different diagnosis and treatment costs).
Scenario analysis showed that the needed time for a
teledermatology GP to complete the teleconsultation
forms is not important in order to reach savings by tele-
dermatology. In our model, this activity took around
three minutes and was almost a third of all teleconsulta-
tion activities [10]. Savings due to teledermatology
might be reached if the time needed to complete
Figure 4 Total costs of the teledermatological and
conventional process (Y-as) for different patient travel
distances to GP (X-axis).
Figure 5 Total costs of the teledermatological and
conventional process (Y-as) for different patient travel
distances to dermatologist (X-axis).
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Page 8 of 10teleconsultation activities by a dermatologist would be
reduced to two minutes instead of eight minutes. This
duration is however out of range from our observations
in the trial, so we consider it unlikely that this scenario
would occur.
In this economic evaluation, the costs were calculated
per care episode which started with the inclusion of the
patient in the trial. The costs before inclusion were not
taken into account. It is possible that in some cases a GP
tried out a treatment which did not work, and then
decided to refer the patient to a dermatologist. In real life
GPs would be able to use teledermatology earlier in the
care episode than what was prescribed in the context of
our trial. Teledermatology potentially lowers the threshold
to consult a dermatologist. This can have a different
impact on costs than what is demonstrated by this study.
The GPs could overuse the service and therefore increase
the total societal costs, but it is also possible that there
would be less inappropriate treatments in GP practice
which would finally lower the societal costs.
Up to our knowledge only one economic evaluation
regarding store-and-forward teledermatology based on
RCT results has been performed. This study by Whited
et al.[14] showed that teledermatology was not cost sav-
ing for the healthcare system compared to the conven-
tional care. The researchers indicated that cost savings
would be more likely if the societal costs would be con-
sidered when teledermatology prevents a third of live
consultations. Based on our study results considering
societal perspective, we agree with this hypothesis by
Whited et al.[14] especially when considering Dutch
travel distances. In the past years, several economic eva-
luations have been performed, especially regarding real-
time teledermatology [15-19]. Loane et al. [15] showed a
positive effect on costs of real time teledermatology in
New Zeeland. In their economic evaluation Armstrong
et al.[19] also showed a positive effect on costs by using
teledermatology but this study was performed from a
healthcare providers’ perspective in the United States.
Because of existing differences between the countries
in fees, distances and health care systems, our study
findings should be generalised with caution. Compari-
sons with other economic evaluations and their findings
should be considered carefully for the same reasons.
Conclusions
Economic evaluation presented in this paper shows that
t h ec h a n c eo ns o c i e t a ls a v i n g sd u et ot h eu s eo ft e l e d e r -
matology is relatively small when teledermatology is
applied to all dermatology referrals. However, our study
shows that savings for the society can be accomplished
when teledermatology is applied in countries with larger
distances to dermatologists or to specific patient groups
where a larger proportion can be treated in a GP practice
without the need for a live dermatological consultation.
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